STOCK TITAN

Candel Therapeutics, Inc. - $CADL STOCK NEWS

Welcome to our dedicated page for Candel Therapeutics news (Ticker: $CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.

Candel Therapeutics, Inc. (CADL) is a Massachusetts-based biotechnology company, also known as Advantagene, Inc., specializing in the development of cutting-edge immuno-oncology platforms aimed at treating solid tumors. The company's focus is on leveraging the body's immune system to combat cancer through innovative viral immunotherapies.

At the core of Candel Therapeutics' technology are two proprietary platforms: the Gene Mediated Cytotoxic Immunotherapy (GMCI™) platform and the RQNestin34.5 platform. Designed as an 'off-the-shelf' solution, GMCI™ aims to generate a personalized and precise immune response against cancer, utilizing the patient's own immune system. The RQNestin34.5 platform, on the other hand, is centered around the use of genetically modified herpes simplex virus (HSV) constructs to target and destroy cancer cells.

As a clinical-stage biopharmaceutical company, Candel Therapeutics is dedicated to translating its scientific advancements into viable treatments for patients. The company has made substantial progress with its platforms, demonstrating promising results in clinical studies aiming to establish the efficacy and safety of these novel therapies.

Among the company's recent highlights is its presentation at the American Society of Clinical Oncology (ASCO), where it shared significant updates on its ongoing projects. Candel Therapeutics continues to engage in strategic partnerships and collaborations to advance its mission of making effective cancer treatments accessible to patients globally.

Candel Therapeutics is committed to maintaining robust investor relations, offering transparent updates and clear communication about its financial health, project milestones, and future directions. The company's leadership frequently engages with stakeholders to ensure alignment with their goals and expectations.

For the latest news and detailed financial information, investors and interested parties can contact Theodore Jenkins, Vice President of Investor Relations and Business Development, at tjenkins@candeltx.com or Kyle Evans, Account Director at ICR Westwicke, at CandelPR@westwicke.com.

Rhea-AI Summary

Candel Therapeutics (CADL) announced its inclusion in the Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective July 1, 2024. This inclusion signifies recognition of Candel’s market capitalization and progress in its clinical programs focused on multimodal biological immunotherapies for cancer. Membership in the Russell 3000 Index means automatic inclusion in either the Russell 1000 or Russell 2000 Index, and other relevant style indexes. The Russell US Indexes, maintained by FTSE Russell, are key benchmarks with approximately $10.5 trillion in assets benchmarked against them as of December 2023.

CEO Paul Peter Tak, MD, PhD, emphasized that this inclusion will increase visibility among investors and enhance engagement with the investment community, supporting Candel’s mission to develop novel immunotherapies for unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.4%
Tags
none
-
Rhea-AI Summary

The FDA has granted Orphan Drug Designation to CAN-3110, Candel Therapeutics' oncolytic viral immunotherapy for treating recurrent high-grade glioma (rHGG). This designation offers developmental incentives and up to 7 years of U.S. market exclusivity upon approval. Previously, CAN-3110 received Fast Track Designation for rHGG. The company is conducting a multi-institutional Phase 1b clinical trial, with initial results indicating strong anti-tumoral responses and extended survival. Candel will present further data on CAN-3110's feasibility and safety at the 2024 ASCO Annual Meeting. CEO Paul Peter Tak emphasized the potential of CAN-3110 and the company's commitment to developing effective treatments for rHGG.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.93%
Tags
-
Rhea-AI Summary

Candel Therapeutics announced promising Phase 2 trial results for CAN-2409, combined with valacyclovir, in NSCLC patients resistant to immune checkpoint inhibitors (ICI). The median overall survival (mOS) was 20.6 months, outperforming the 11.6 months mOS of standard docetaxel-based chemotherapy. The treatment significantly increased cytotoxic and memory T cells, enhancing systemic immunity, and showed efficacy on both treated and untreated tumors. Additionally, CAN-2409 maintained a favorable safety profile, with mostly mild adverse events. These findings underscore the potential of CAN-2409 in treating advanced NSCLC and will be presented at the 2024 ASCO Annual Meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.03%
Tags
Rhea-AI Summary

Candel Therapeutics (Nasdaq: CADL), a clinical-stage biopharmaceutical company, will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 5:30 p.m. ET. Paul Peter Tak, Candel’s President and CEO, will provide a company overview. The presentation will be available via a live webcast on the company’s website, with a replay accessible for up to 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.77%
Tags
conferences
-
Rhea-AI Summary

Candel Therapeutics will host a webcasted R&D breakfast panel during the 2024 ASCO Annual Meeting on June 3, 2024, at 7:00 AM Central Time. The event will focus on discussing topline overall survival data from the Phase 2 clinical trial of CAN-2409, a multimodal biological immunotherapy candidate for Non-Small Cell Lung Cancer (NSCLC). The panel, moderated by Candel's CEO Paul Peter Tak, will feature prominent medical and scientific leaders, including Dr. Charu Aggarwal from the University of Pennsylvania, Dr. Roy S. Herbst from Yale School of Medicine, and Dr. Daniel H. Sterman from NYU Langone Health. A live webcast and an archived replay will be available on Candel's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
conferences
-
Rhea-AI Summary

Candel Therapeutics (Nasdaq: CADL) reported its Q1 2024 financial results and corporate highlights. The company showcased positive survival data from its ongoing phase 2 clinical trial of CAN-2409 in pancreatic cancer, with a median overall survival of 28.8 months compared to 12.5 months for the control group. CAN-2409 also received FDA Fast Track and Orphan Drug Designations.

Topline survival data for CAN-2409 in NSCLC will be presented at ASCO on June 3, 2024. The company's enLIGHTEN™ platform revealed a new immunotherapy candidate at the AACR Annual Meeting.

Financially, Candel's Q1 2024 research and development expenses decreased to $4.1 million from $5.5 million in Q1 2023. General and administrative expenses also decreased to $3.8 million from $4.2 million. The net loss stood at $8.2 million, down from $8.8 million. Cash reserves were $25.7 million as of March 31, 2024, providing sufficient funds into Q4 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
Rhea-AI Summary
Candel Therapeutics, a biopharmaceutical company, announced two abstracts accepted for presentation at the 2024 ASCO Annual Meeting. One abstract focuses on a phase 1 clinical trial of CAN-3110 for recurrent high-grade glioma, showcasing feasibility and tolerability. The second abstract presents overall survival data from a phase 2 trial of CAN-2409 plus valacyclovir for NSCLC patients with an inadequate response to front line therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.28%
Tags
conferences
-
Rhea-AI Summary
Candel Therapeutics, Inc. (CADL) receives Orphan Drug Designation from the FDA for CAN-2409, a promising multimodal biological immunotherapy candidate for pancreatic cancer. Clinical trial data shows significant improvement in overall survival rates and safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.75%
Tags
-
Rhea-AI Summary
Candel Therapeutics, Inc. presents a first-in-class immunotherapy candidate for solid tumors, inducing tertiary lymphoid structures for improved anti-tumor immunity. The candidate, developed from the enLIGHTEN™ Discovery Platform, shows promising results in inhibiting tumor growth and enhancing response to immune checkpoint inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.84%
Tags
Rhea-AI Summary
Candel Therapeutics (CADL) announces positive interim data showing significant improvements in overall survival in patients with pancreatic cancer treated with CAN-2409. Survival rates at 24 and 36 months were notably higher in the CAN-2409 group compared to the control group. The treatment was well tolerated with no new safety signals observed. The FDA granted Fast Track Designation for CAN-2409 in combination with valacyclovir for pancreatic cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
280.95%
Tags

FAQ

What does Candel Therapeutics, Inc. specialize in?

Candel Therapeutics focuses on developing immuno-oncology platforms aimed at treating solid tumors using viral immunotherapies.

What are the main platforms developed by Candel Therapeutics?

The main platforms are the Gene Mediated Cytotoxic Immunotherapy (GMCI™) platform and the RQNestin34.5 platform.

How does the GMCI™ platform work?

The GMCI™ platform generates a personalized immune response against cancer using the patient's own immune system.

What is unique about the RQNestin34.5 platform?

The RQNestin34.5 platform uses genetically modified herpes simplex virus (HSV) constructs to target and destroy cancer cells.

Is Candel Therapeutics a clinical-stage company?

Yes, Candel Therapeutics is a clinical-stage biopharmaceutical company focused on viral immunotherapies for cancer treatment.

What recent achievements has Candel Therapeutics made?

Candel Therapeutics presented significant updates at the American Society of Clinical Oncology (ASCO) and continues to progress in its clinical studies.

Who can I contact for investor relations at Candel Therapeutics?

You can contact Theodore Jenkins, Vice President of Investor Relations and Business Development, at tjenkins@candeltx.com.

Who handles media inquiries for Candel Therapeutics?

Media inquiries are handled by Kyle Evans, Account Director at ICR Westwicke, reachable at CandelPR@westwicke.com.

What types of cancer are targeted by Candel Therapeutics' platforms?

Candel Therapeutics focuses on treating solid tumors through its immuno-oncology platforms.

Where is Candel Therapeutics based?

Candel Therapeutics is based in Massachusetts, USA.

Candel Therapeutics, Inc.

Nasdaq:CADL

CADL Rankings

CADL Stock Data

224.66M
18.05M
34.72%
16.46%
0.55%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
NEEDHAM

About CADL

also known as advantagene. inc., we are a massachusetts-based biotechnology company developing our proprietary immuno-oncology platforms for the treatment of solid tumors, including our gene mediated cytotoxic (gmci™) platform and our rqnestin34.5 platform. gmci™ is an "off-the-shelf" immunotherapy designed to generate a personalized, robust, and precise systemic response from the patient's own immune system against his or her cancer.